<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30406761</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1305-3612</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>24</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                    </PubDate>                </JournalIssue>                <Title>Diagnostic and interventional radiology (Ankara, Turkey)</Title>                <ISOAbbreviation>Diagn Interv Radiol</ISOAbbreviation>            </Journal>            <ArticleTitle>Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT.</ArticleTitle>            <Pagination>                <MedlinePgn>336</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.5152/dir.2018.17367</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We aimed to quantitatively evaluate volumetric metabolic tumor burden including metabolic tumor volume and total lesion glycolysis in different molecular subtypes of breast cancer using 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This study involved 99 female patients with pathologic diagnosis of primary breast cancer, who underwent 18F-FDG PET/CT before any therapy. Patients were divided into subtypes of luminal A, luminal B, ERBB2+, and basal-like based on the immunohistochemistry results. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) before and after correction for lean body mass were achieved and compared. Correlations between metabolic tumor burden and Ki-67 were analyzed and diagnostic performances of volumetric metabolic parameters were evaluated.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">TLG values were significantly different between each molecular subtype, while MTV values were not. Values of TLG were significantly reduced after normalizing for lean body mass in each subtype. Both of them showed correlations with Ki-67 and presented high diagnostic ability in identifying patients with basal-like breast cancer from the rest. TLGs before and after normalizing for the lean body mass had similar diagnostic performances in differentiating patients of basal-like subtype from the rest.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Metabolic tumor burden could comprehensively reflect tumor metabolic differences of molecular subtypes of breast cancer, and it can serve to help differentiate patients with basal-like breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Wei</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Imaging and Nuclear Medicine Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhu</LastName>                    <ForeName>Lei</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Imaging and Nuclear Medicine Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yu</LastName>                    <ForeName>Xiaozhou</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Imaging and Nuclear Medicine Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fu</LastName>                    <ForeName>Qiang</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Imaging and Nuclear Medicine Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Wengui</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Imaging and Nuclear Medicine Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Ping</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Imaging and Nuclear Medicine and Radiation Oncology Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Cancer Prevention and Therapy Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Turkey</Country>            <MedlineTA>Diagn Interv Radiol</MedlineTA>            <NlmUniqueID>101241152</NlmUniqueID>            <ISSNLinking>1305-3825</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30406761</ArticleId>            <ArticleId IdType="doi">10.5152/dir.2018.17367</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>